がん免疫療法の世界市場レポート 2025年

がん免疫療法の市場規模は、今後数年で急成長が見込まれます。2029年にはCAGR11.6％で1,946億4,000万米ドルに成長します。予測期間の成長は、がん治療における新規免疫療法の承認増加、個別化医療に対する需要の高まり、がんと診断されるケースの増加、最先端の治療法を導入するための臨床試験への投資の増加、がん免疫療法に対する意識の高まりなどに起因しています。予測期間における主な動向としては、CAR T細胞を含む養子細胞療法の出現、がん免疫療法における腫瘍溶解性ウイルスの探求、個別化がんワクチンの開発、免疫療法研究における人工知能の活用、治療決定における実世界のエビデンスと患者の転帰の重視の高まりなどが挙げられます。

がん罹患率の上昇はがん免疫療法市場を促進すると予想されます。世界中でがん罹患数が増加している要因には、タバコ、アルコール、肥満、座りがちなライフスタイル、環境要因などがあります。このようながん患者の増加は、がん免疫療法の需要を押し上げると予想されます。患者たちは、より回復力が高く、痛みを最小限に抑えた治療に投資するようになっているからです。例えば、ベルギーに本部を置く欧州委員会の共同研究センターである欧州連合科学ハブによると、2023年10月、新たながん患者はその前の2年間で2.3％増加し、2022年には274万人に達しました。同様に、がんによる死亡者数は過去2年間で2.4％増加しました。したがって、がん罹患率の増加は、予測期間中にがん免疫療法の需要を押し上げると予想されます。

バイオシミラーの増加により、がん免疫療法市場の成長は今後数年で促進されると予想されます。バイオシミラーとは、既存の承認生物製剤（基準製剤）と非常によく似た生物学的医療製品であり、基準製剤と安全性、有効性、品質において臨床的に重要な差異がないように設計されています。バイオシミラー医薬品は、治療へのアクセシビリティを高め、競争を刺激し、価格を下げ、がん患者により持続可能で多様な治療選択肢を提供するため、がん免疫療法において大きな可能性を秘めています。例えば、米国のバイオ医薬品会社であるAmgen Inc.によると、2022年第2四半期時点でFDAのバイオシミラー開発プログラムに登録されたバイオシミラー医薬品は96品目であり、70％近く増加しています。したがって、バイオシミラーの増加が、がん免疫療法市場を牽引しています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界のがん免疫療法市場のPESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界のがん免疫療法市場の成長率分析
• 世界のがん免疫療法市場の実績：規模と成長、2019～2024年
• 世界のがん免疫療法市場の予測：規模と成長、2024～2029年、2034年
• 世界のがん免疫療法総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界のがん免疫療法市場：製品別、実績と予測、2019～2024年、2024～2029年、2034年
• モノクローナル抗体
• チェックポイント阻害剤
• 免疫調節薬
• ワクチン
• 細胞療法
• 世界のがん免疫療法市場：用途別、実績と予測、2019～2024年、2024～2029年、2034年
• 肺がん
• 乳がん
• 大腸がん
• メラノーマ
• 前立腺がん
• 多発性骨髄腫
• 世界のがん免疫療法市場：エンドユーザー別、実績と予測、2019～2024年、2024～2029年、2034年
• 病院
• がん研究センター
• クリニック
• 世界のがん免疫療法市場：モノクローナル抗体のサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• キメラモノクローナル抗体
• ヒト化モノクローナル抗体
• 完全ヒト型モノクローナル抗体
• 世界のがん免疫療法市場：チェックポイント阻害剤のサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• PD-1阻害剤
• PD-L1阻害剤
• CTLA-4阻害剤
• 世界のがん免疫療法市場：免疫調節剤のサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• サイトカイン
• 腫瘍溶解性ウイルス
• トール様受容体（TLR）アゴニスト
• 世界のがん免疫療法市場：ワクチンのサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• がん予防ワクチン
• 治療用がんワクチン
• 世界のがん免疫療法市場：細胞療法のサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• CAR T細胞療法
• TCR療法
• ナチュラルキラー（NK）細胞療法

第7章 地域別・国別分析

• 世界のがん免疫療法市場：地域別、実績と予測、2019～2024年、2024～2029年、2034年
• 世界のがん免疫療法市場：国別、実績と予測、2019～2024年、2024～2029年、2034年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• がん免疫療法市場：競合情勢
• がん免疫療法市場：企業プロファイル
  • Amgen Inc. Overview, Products and Services, Strategy and Financial Analysis
  • AstraZeneca PLC Overview, Products and Services, Strategy and Financial Analysis
  • F. Hoffmann-La Roche Ltd Overview, Products and Services, Strategy and Financial Analysis
  • Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • Eli Lilly and Company Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• 3D Signatures Inc.
• Adaptive Biotechnologies Corp.
• Argos Therapeutics Inc.
• Bristol-Myers Squibb Company
• Cell Medica Limited
• Cellular Biomedicine Group Inc.
• Gilead Sciences Inc.
• Gradalis Inc.
• Immatics Biotechnologies GmbH
• Iovance Biotherapeutics Inc.
• Juno Therapeutics LLC
• Kura Oncology Inc.
• MacroGenics Inc.
• Merck & Co. Inc.
• Neon Therapeutics Inc.

第32章 世界市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 市場の最近の動向

第35章 市場の潜在力が高い国、セグメント、戦略

• がん免疫療法市場2029年-最も新しい機会を提供する国
• がん免疫療法市場2029年-最も新しい機会を提供するセグメント
• がん免疫療法市場2029年-成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Cancer immunotherapy refers to a type of cancer therapy that strengthens your body's defenses against the disease. Your body's immune system aids in the defense against infections and other disorders. White blood cells, organs, and lymphatic system tissues make up this substance. Cancer immunotherapy comes in various forms, such as cytokines and vaccines, adoptive cell therapies, oncolytic viruses, tumor-infecting viruses, and others.

The main types of products of cancer immunotherapy are monoclonal antibodies, checkpoint inhibitors, immunomodulators, vaccines, and cell therapy. Monoclonal antibodies are man-made proteins that function in the immune system such as human antibodies. Cancer immunotherapy is used to treat lung cancer, breast cancer, colorectal cancer, melanoma, prostate cancer, and multiple myeloma. These are used in hospitals, cancer research centers, and clinics.

The cancer immunotheraphy market research report is one of a series of new reports from The Business Research Company that provides cancer immunotheraphy market statistics, including cancer immunotheraphy industry global market size, regional shares, competitors with a cancer immunotheraphy market share, detailed cancer immunotheraphy market segments, market trends and opportunities, and any further data you may need to thrive in the cancer immunotheraphy industry. This cancer immunotheraphy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The cancer immunotherapy market size has grown rapidly in recent years. It will grow from $110.91 billion in 2024 to $125.68 billion in 2025 at a compound annual growth rate (CAGR) of 13.3%. The growth in the historic period can be attributed to rising prevalence of cancer, increased adoption of immunotherapy over traditionalTherapy, growing r&d activities forThe development of targeted diseases, increased effectivity and accuracy of newerTherapies, growing recognition of The limitations of traditional cancer treatments.

The cancer immunotherapy market size is expected to see rapid growth in the next few years. It will grow to $194.64 billion in 2029 at a compound annual growth rate (CAGR) of 11.6%. The growth in the forecast period can be attributed to increasing approval of novel immunotherapies for cancer treatment, growing demand for personalized medicine, rising cases of people being detected with cancer, increasing investment in clinical trials to introduce cutting-edge treatments, growing awareness about cancer immunotherapy. Major trends in the forecast period include emergence of adoptive cell therapies, including car-t cells, exploration of oncolytic viruses in cancer immunotherapy, development of personalized cancer vaccines, utilization of artificial intelligence in immunotherapy research, increasing emphasis on real-world evidence and patient outcomes in treatment decisions.

The rise in cancer incidence is expected to propel the cancer immunotherapy market. The factors contributing to the growth in cancer cases across the globe include tobacco, alcohol, obesity, a sedentary lifestyle, and environmental factors. This growth in cancer cases is expected to boost demand for cancer immunotherapies, as patients are increasingly investing in medical treatments with greater recovery and minimal pain. For instance, in October 2023, according to the European Union Science Hub, a Belgium-based European Commission's Joint Research Centre, new cancer cases increased by 2. 3% during the preceding two years, reaching 2. 74 million in 2022. Similarly, cancer fatalities increased by 2. 4% during the preceding two years. Therefore, the increase in cancer incidence is expected to boost demand for cancer immunotherapy during forecast period.

The increasing emergence of biosimilars is expected to propel the growth of the cancer immunotherapy market in the coming years. Biosimilars are biological medical products that are very similar to an existing authorized biological drug (the reference product) and are designed to have no clinically significant variations in terms of safety, effectiveness, and quality from the reference product. Biosimilars have great potential in cancer immunotherapy because they increase treatment accessibility, stimulate competition, lower prices, and provide more sustainable and diverse therapeutic alternatives for cancer patients. For instance, in 2022, according to Amgen Inc., a US-based biopharmaceutical company, the FDA reported 96 proposed biosimilar drugs registered in the FDA's Biosimilar Development Program as of Q2 2022, a nearly 70% increase. Therefore, the increasing emergence of biosimilars is driving the cancer immunotherapy market.

Advanced technologies used in cancer immunotherapy are a key trend gaining popularity in the cancer immunotherapy market. There has been a surge of new technologies and various therapies to help the immune system identify and attack tumors using different therapies and technologies such as immuno-oncology, cryoablation, bone marrow transplant, and radiation therapy. These technologies can make a significant difference in cancer treatment and cure. For instance, in October 2022, AstraZeneca plc, a UK-based pharmaceutical and biotechnology company, announced that it had received approval for its Capivasertib in combination with Faslodex. This drug is a cancer immunotherapeutic developed for the treatment of breast cancer and is effective in following recurrence or advancement on or after endocrine therapy in locally progressed or metastatic breast cancer with low or negative human epidermal growth factor receptor 2 (HER2).

Major companies operating in the cancer immunotherapy market are focusing on developing innovative products, such as Imjudo in combination with Imfinzi, to better meet the needs of their existing consumers. Imjudo, a combination of Imfinzi (durvalumab) and tremelimumab, is a possible dual immune checkpoint inhibitor in cancer immunotherapy. For instance, in October 2022, AstraZeneca Plc, a UK-based biotechnology and pharmaceutical company, announced the approval of Imjudo and Imfinzi for the treatment of unresectable hepatocellular carcinoma (HCC). The STRIDE regimen (Single Tremelimumab Regular Interval Durvalumab) refers to the innovative dose and schedule of the combination, which involves a single dose of the anti-CTLA-4 antibody Imjudo 300mg combined with the anti-PD-L1 antibody Imfinzi 1500mg followed by Imfinzi every four weeks.

In July 2024, Boehringer Ingelheim, a pharmaceutical company based in Germany, acquired Nerio Therapeutics for $1.3 billion. This acquisition will greatly strengthen Boehringer Ingelheim's immuno-oncology portfolio by incorporating Nerio's innovative preclinical program centered on immune checkpoint inhibitors. Nerio Therapeutics, a biotech company located in the US, specializes in drug discovery and development, particularly focusing on phosphatases, which are a challenging but highly promising class of therapeutic protein targets.

Major companies operating in the cancer immunotherapy market include Amgen Inc., AstraZeneca PLC, F. Hoffmann-La Roche Ltd, Bayer AG, Eli Lilly and Company, 3D Signatures Inc., Adaptive Biotechnologies Corp., Argos Therapeutics Inc., Bristol-Myers Squibb Company, Cell Medica Limited, Cellular Biomedicine Group Inc., Gilead Sciences Inc., Gradalis Inc., Immatics Biotechnologies GmbH, Iovance Biotherapeutics Inc., Juno Therapeutics LLC, Kura Oncology Inc., MacroGenics Inc., Merck & Co. Inc., Neon Therapeutics Inc., Neovii Biotech GmbH, Novartis International AG, Pfizer Inc., Pulse Biosciences Inc., Regeneron Pharmaceuticals Inc., Roche Holding AG, Targovax ASA, Tessa Therapeutics Pte Ltd., TILT Biotherapeutics Ltd., Turnstone Biologics Corp., Xencor Inc.

North America was the largest region in the cancer immunotherapy market in 2024 and is also expected to be the fastest-growing region in the forecast period. The regions covered in the cancer immunotherapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the cancer immunotherapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain.

The cancer immunotherapy market includes revenues earned by entities by helping the immune system fight cancer. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Cancer Immunotherapy Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on cancer immunotherapy market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for cancer immunotherapy ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The cancer immunotherapy market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Product: Monoclonal Antibodies, Checkpoint Inhibitors, Immunomodulators, Vaccines, Cell Therapy
• 2) By Application: Lung Cancer, Breast Cancer, Colorectal Cancer, Melanoma, Prostate Cancer, Multiple Myeloma
• 3) By End User: Hospitals, Cancer Research Centers, Clinics
• Subsegments:
• 1) By Monoclonal Antibodies: Chimeric Monoclonal Antibodies; Humanized Monoclonal Antibodies; Fully Human Monoclonal Antibodies
• 2) By Checkpoint Inhibitors: PD-1 Inhibitors; PD-L1 Inhibitors; CTLA-4 Inhibitors
• 3) By Immunomodulators: Cytokines; Oncolytic Viruses; Toll-Like Receptor (TLR) Agonists
• 4) By Vaccines: Preventive Cancer Vaccines; Therapeutic Cancer Vaccines
• 5) By Cell Therapy: CAR T-Cell Therapy; TCR Therapy; Natural Killer (NK) Cell Therapy
• Companies Mentioned: Amgen Inc.; AstraZeneca PLC; F. Hoffmann-La Roche Ltd; Bayer AG; Eli Lilly and Company
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Cancer Immunotherapy Market Characteristics

3. Cancer Immunotherapy Market Trends And Strategies

4. Cancer Immunotherapy Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Cancer Immunotherapy Growth Analysis And Strategic Analysis Framework

• 5.1. Global Cancer Immunotherapy PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Cancer Immunotherapy Market Growth Rate Analysis
• 5.4. Global Cancer Immunotherapy Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Cancer Immunotherapy Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Cancer Immunotherapy Total Addressable Market (TAM)

6. Cancer Immunotherapy Market Segmentation

• 6.1. Global Cancer Immunotherapy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Monoclonal Antibodies
• Checkpoint Inhibitors
• Immunomodulators
• Vaccines
• Cell Therapy
• 6.2. Global Cancer Immunotherapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Lung Cancer
• Breast Cancer
• Colorectal Cancer
• Melanoma
• Prostate Cancer
• Multiple Myeloma
• 6.3. Global Cancer Immunotherapy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Cancer Research Centers
• Clinics
• 6.4. Global Cancer Immunotherapy Market, Sub-Segmentation Of Monoclonal Antibodies, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Chimeric Monoclonal Antibodies
• Humanized Monoclonal Antibodies
• Fully Human Monoclonal Antibodies
• 6.5. Global Cancer Immunotherapy Market, Sub-Segmentation Of Checkpoint Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• PD-1 Inhibitors
• PD-L1 Inhibitors
• CTLA-4 Inhibitors
• 6.6. Global Cancer Immunotherapy Market, Sub-Segmentation Of Immunomodulators, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Cytokines
• Oncolytic Viruses
• Toll-Like Receptor (TLR) Agonists
• 6.7. Global Cancer Immunotherapy Market, Sub-Segmentation Of Vaccines, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Preventive Cancer Vaccines
• Therapeutic Cancer Vaccines
• 6.8. Global Cancer Immunotherapy Market, Sub-Segmentation Of Cell Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• CAR T-Cell Therapy
• TCR Therapy
• Natural Killer (NK) Cell Therapy

7. Cancer Immunotherapy Market Regional And Country Analysis

• 7.1. Global Cancer Immunotherapy Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Cancer Immunotherapy Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Cancer Immunotherapy Market

• 8.1. Asia-Pacific Cancer Immunotherapy Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Cancer Immunotherapy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Cancer Immunotherapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Cancer Immunotherapy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Cancer Immunotherapy Market

• 9.1. China Cancer Immunotherapy Market Overview
• 9.2. China Cancer Immunotherapy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Cancer Immunotherapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Cancer Immunotherapy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Cancer Immunotherapy Market

• 10.1. India Cancer Immunotherapy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Cancer Immunotherapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Cancer Immunotherapy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Cancer Immunotherapy Market

• 11.1. Japan Cancer Immunotherapy Market Overview
• 11.2. Japan Cancer Immunotherapy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Cancer Immunotherapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Cancer Immunotherapy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Cancer Immunotherapy Market

• 12.1. Australia Cancer Immunotherapy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Cancer Immunotherapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Cancer Immunotherapy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Cancer Immunotherapy Market

• 13.1. Indonesia Cancer Immunotherapy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Cancer Immunotherapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Cancer Immunotherapy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Cancer Immunotherapy Market

• 14.1. South Korea Cancer Immunotherapy Market Overview
• 14.2. South Korea Cancer Immunotherapy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Cancer Immunotherapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Cancer Immunotherapy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Cancer Immunotherapy Market

• 15.1. Western Europe Cancer Immunotherapy Market Overview
• 15.2. Western Europe Cancer Immunotherapy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Cancer Immunotherapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Cancer Immunotherapy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Cancer Immunotherapy Market

• 16.1. UK Cancer Immunotherapy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Cancer Immunotherapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Cancer Immunotherapy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Cancer Immunotherapy Market

• 17.1. Germany Cancer Immunotherapy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Cancer Immunotherapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Cancer Immunotherapy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Cancer Immunotherapy Market

• 18.1. France Cancer Immunotherapy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Cancer Immunotherapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Cancer Immunotherapy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Cancer Immunotherapy Market

• 19.1. Italy Cancer Immunotherapy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Cancer Immunotherapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Cancer Immunotherapy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Cancer Immunotherapy Market

• 20.1. Spain Cancer Immunotherapy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Cancer Immunotherapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Cancer Immunotherapy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Cancer Immunotherapy Market

• 21.1. Eastern Europe Cancer Immunotherapy Market Overview
• 21.2. Eastern Europe Cancer Immunotherapy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Cancer Immunotherapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Cancer Immunotherapy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Cancer Immunotherapy Market

• 22.1. Russia Cancer Immunotherapy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Cancer Immunotherapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Cancer Immunotherapy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Cancer Immunotherapy Market

• 23.1. North America Cancer Immunotherapy Market Overview
• 23.2. North America Cancer Immunotherapy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Cancer Immunotherapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Cancer Immunotherapy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Cancer Immunotherapy Market

• 24.1. USA Cancer Immunotherapy Market Overview
• 24.2. USA Cancer Immunotherapy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Cancer Immunotherapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Cancer Immunotherapy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Cancer Immunotherapy Market

• 25.1. Canada Cancer Immunotherapy Market Overview
• 25.2. Canada Cancer Immunotherapy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Cancer Immunotherapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Cancer Immunotherapy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Cancer Immunotherapy Market

• 26.1. South America Cancer Immunotherapy Market Overview
• 26.2. South America Cancer Immunotherapy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Cancer Immunotherapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Cancer Immunotherapy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Cancer Immunotherapy Market

• 27.1. Brazil Cancer Immunotherapy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Cancer Immunotherapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Cancer Immunotherapy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Cancer Immunotherapy Market

• 28.1. Middle East Cancer Immunotherapy Market Overview
• 28.2. Middle East Cancer Immunotherapy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Cancer Immunotherapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Cancer Immunotherapy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Cancer Immunotherapy Market

• 29.1. Africa Cancer Immunotherapy Market Overview
• 29.2. Africa Cancer Immunotherapy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Cancer Immunotherapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Cancer Immunotherapy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Cancer Immunotherapy Market Competitive Landscape And Company Profiles

• 30.1. Cancer Immunotherapy Market Competitive Landscape
• 30.2. Cancer Immunotherapy Market Company Profiles
  • 30.2.1. Amgen Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. AstraZeneca PLC Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. F. Hoffmann-La Roche Ltd Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Eli Lilly and Company Overview, Products and Services, Strategy and Financial Analysis

31. Cancer Immunotherapy Market Other Major And Innovative Companies

• 31.1. 3D Signatures Inc.
• 31.2. Adaptive Biotechnologies Corp.
• 31.3. Argos Therapeutics Inc.
• 31.4. Bristol-Myers Squibb Company
• 31.5. Cell Medica Limited
• 31.6. Cellular Biomedicine Group Inc.
• 31.7. Gilead Sciences Inc.
• 31.8. Gradalis Inc.
• 31.9. Immatics Biotechnologies GmbH
• 31.10. Iovance Biotherapeutics Inc.
• 31.11. Juno Therapeutics LLC
• 31.12. Kura Oncology Inc.
• 31.13. MacroGenics Inc.
• 31.14. Merck & Co. Inc.
• 31.15. Neon Therapeutics Inc.

32. Global Cancer Immunotherapy Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Cancer Immunotherapy Market

34. Recent Developments In The Cancer Immunotherapy Market

35. Cancer Immunotherapy Market High Potential Countries, Segments and Strategies

• 35.1 Cancer Immunotherapy Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Cancer Immunotherapy Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Cancer Immunotherapy Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer